{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T19:40:29Z","timestamp":1785354029554,"version":"3.55.0"},"reference-count":14,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2007,1,1]],"date-time":"2007-01-01T00:00:00Z","timestamp":1167609600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2007,1,1]],"date-time":"2007-01-01T00:00:00Z","timestamp":1167609600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,12]],"date-time":"2023-08-12T00:00:00Z","timestamp":1691798400000},"content-version":"vor","delay-in-days":6067,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2007,1]]},"DOI":"10.1016\/j.nurt.2006.11.006","type":"journal-article","created":{"date-parts":[[2007,1,8]],"date-time":"2007-01-08T14:22:02Z","timestamp":1168266122000},"page":"155-162","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":114,"title":["Rufinamide"],"prefix":"10.1016","volume":"4","author":[{"given":"Santiago","family":"Arroyo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nurt.2006.11.006_bib1","doi-asserted-by":"crossref","first-page":"249","DOI":"10.2165\/00126839-200506040-00010","article-title":"Rufinamide: CGP 33101, E 2080, RUF 331, Xilep","volume":"6","year":"2005","journal-title":"Drugs R D"},{"issue":"suppl 6","key":"10.1016\/j.nurt.2006.11.006_bib2","first-page":"375","article-title":"Effects of rufinamide on sodium-dependent action potential firing and sodium currents of rodent central neurons","volume":"46","author":"McLean","year":"2005","journal-title":"Epilepsia"},{"issue":"suppl 6","key":"10.1016\/j.nurt.2006.11.006_bib3","first-page":"373","article-title":"Rufinamide (CGP 33101): a broad-spectrum anticonvulsant with excellent tolerability profile in rodents","volume":"46","author":"White","year":"2005","journal-title":"Epilepsia"},{"key":"10.1016\/j.nurt.2006.11.006_bib4","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/00045391-199410000-00008","article-title":"Pharmacokinetics of a new anticonvulsant (CGP 33101) in epileptic male patients and healthy male subjects after single ascending oral doses of 400\u20131200 mg","volume":"1","author":"Brunner","year":"1994","journal-title":"Am J Ther"},{"key":"10.1016\/j.nurt.2006.11.006_bib5","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1002\/(SICI)1099-081X(199805)19:4<259::AID-BDD98>3.0.CO;2-V","article-title":"The influence of food on the disposition of the antiepileptic rufinamide in healthy volunteers","volume":"19","author":"Cardot","year":"1998","journal-title":"Biopharm Drug Dispos"},{"issue":"suppl 8","key":"10.1016\/j.nurt.2006.11.006_bib6","first-page":"193","article-title":"Pharmacokinetics and safety of ascending doses of adjunctive rufinamide in pediatric patients with inadequately controlled seizures","volume":"46","author":"Arroyo","year":"2005","journal-title":"Epilepsia"},{"issue":"suppl 6","key":"10.1016\/j.nurt.2006.11.006_bib7","first-page":"59","article-title":"A pharmacokinetic evaluation of rufinamide in elderly and younger subjects","volume":"39","author":"Chang","year":"1998","journal-title":"Epilepsia"},{"issue":"suppl 8","key":"10.1016\/j.nurt.2006.11.006_bib8","first-page":"210","article-title":"Population pharmacokinetic drug\u2013drug interaction analyses of rufinamide studies in patients with epilepsy","volume":"46","author":"Fuseau","year":"2005","journal-title":"Epilepsia"},{"issue":"suppl 2","key":"10.1016\/j.nurt.2006.11.006_bib9","first-page":"A35","article-title":"Efficacy and safety of rufinamide as adjunctive therapy in adult patients with inadequately controlled partial seizures","volume":"66","author":"Brodie","year":"2006","journal-title":"Neurology"},{"issue":"suppl 2","key":"10.1016\/j.nurt.2006.11.006_bib10","first-page":"A37","article-title":"Dose-response relationships of rufinamide in patients with inadequately controlled partial seizures","volume":"66","author":"Elger","year":"2006","journal-title":"Neurology"},{"issue":"suppl 8","key":"10.1016\/j.nurt.2006.11.006_bib11","first-page":"218","article-title":"Efficacy and safety of high- versus low-dose rufinamide monotherapy in patients with inadequately controlled partial seizures","volume":"46","author":"Todorov","year":"2005","journal-title":"Epilepsia"},{"issue":"suppl 1","key":"10.1016\/j.nurt.2006.11.006_bib12","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1212\/WNL.64.10.1826","article-title":"Efficacy and safety of rufinamide adjunctive therapy in patients with Lennox\u2013Gastaut Syndrome (LGS): a multicenter, randomized, double-blind, placebo-controlled, parallel trial","volume":"64","author":"Glauser","year":"2005","journal-title":"Neurology"},{"issue":"suppl 6","key":"10.1016\/j.nurt.2006.11.006_bib13","first-page":"408","article-title":"Open-label extension study of the efficacy and safety of rufinamide adjunctive therapy in patients with Lennox\u2013Gastaut syndrome","volume":"46","author":"Glauser","year":"2005","journal-title":"Epilepsia"},{"issue":"suppl 8","key":"10.1016\/j.nurt.2006.11.006_bib14","first-page":"213","article-title":"Short and long-term safety of rufinamide in patients with epilepsy","volume":"46","author":"Krauss","year":"2005","journal-title":"Epilepsia"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923006839?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923006839?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.springerlink.com\/index\/pdf\/10.1016\/j.nurt.2006.11.006","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T06:40:24Z","timestamp":1761806424000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747923006839"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,1]]},"references-count":14,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2007,1]]}},"alternative-id":["S1878747923006839"],"URL":"https:\/\/doi.org\/10.1016\/j.nurt.2006.11.006","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2007,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rufinamide","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nurt.2006.11.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2007 The American Society for Experimental NeuroTherapeutics, Inc. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}